Reported revenues of $227.2m, down 17% on 1HFY19 • Reported EBITDA of $34.6m, a decrease of 47% on 1HFY19 • Underlying EBITDA of $47.4m, a decrease of 42% on 1HFY19 • Reported net loss after tax of $17.5m driven by lower earnings and restructuring expenses • Net operating cashflow of $46.2m down 14% on 1HFY19 • Licensed novel oral contraceptive E4/DRSP in the US • Generic NUVARING® complete response letter submitted to the US Food and Drug Administration (FDA) with launch anticipated in CY20 • Filed three generic products with the FDA including a potential first-to-market women’s health product • Significant spend base reduction of $20m (annualised)
MYX Price at posting:
40.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)